Understand the source comparison
Selank Amidate Semax Amidate Stack Protocol: Administration Comparison
The table below compares the three primary administration approaches used in published selank amidate semax amidate stack protocol research. Each route offers distinct pharmacokinetic profiles and practical trade-offs. Intranasal (solution) 60–70% 15–30 minute
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below compares the three primary administration approaches used in published selank amidate semax amidate stack protocol research. Each route offers distinct pharmacokinetic profiles and practical trade-offs.
- Intranasal (solution)
- 60–70%
- 15–30 minutes
- 4–6 hours per dose
- Non-invasive, rapid CNS delivery via olfactory pathway, no injection training required, volume limited to 100–200 mcL per nostril
- Preferred for behavioral studies requiring rapid onset and minimal stress from administration procedure
- Subcutaneous injection
- 80–85%
- 30–60 minutes
- 6–8 hours per dose
- Higher bioavailability, consistent dosing accuracy, requires sterile technique and injection site rotation to avoid tissue irritation
- Optimal for dose-response studies where precision and reproducibility outweigh convenience
- Oral (experimental)
- 5–15%
- 60–90 minutes
- 2–4 hours per dose
- Convenient but poor bioavailability due to peptide degradation in GI tract, amidate protection insufficient to overcome first-pass metabolism
- Not recommended. Insufficient plasma levels reached even at high doses
- Intranasal delivery remains the gold standard for dual-peptide cognitive research because it combines reasonable bioavailability with minimal procedural stress, which is critical when studying anxiety-related endpoints. Subcutaneous administration is reserved for studies where dose precision justifies the added complexity.